- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: Nec-1
Necrostatin-1 (Nec-1)是一種特異性RIP1 (RIPK1)抑制劑,抑制TNF-α誘導的細胞壞死,在293T細胞中EC50為490 nM。Necrostatin-1也可抑制 IDO、細胞自噬和凋亡。
Necrostatin-1 Chemical Structure
CAS: 4311-88-0
相關(guān)靶點 | RIP1 kinase RIP2 kinase RIP3 kinase RIP 1 Kinase | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | GSK'872 Necrostatin 2 racemate (Nec-1s) Mito-TEMPO RIPA-56 GSK2982772 GSK'963 GSK583 GSK2983559 (compound 3) Resibufogenin GSK'547 ICCB-19 hydrochloride HS-1371 GSK481 | 點擊展開 |
相關(guān)化合物庫 | 自噬化合物庫 凋亡分子化合物庫 鐵死亡化合物庫 細胞焦亡化合物庫 線粒體靶向化合物庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
L929 | Growth Inhibition Assay | 2/5?μg/ml? | 24?h | reverses the cell growth inhibition and cell death induced by TNFα alone as well as TNFα?+?zVAD | 23941769 |
L929 | Function Assay | 2?μg/ml? | 24?h | promots caspase-6 (p20) activity and procaspase-6 cleavage | 23941769 |
L929 | Function Assay | 5?μg/ml | 24?h | blocks zVAD induced necroptosis and autophagy | 23941769 |
C6 | Cell Viability Assay | 1 mmol/L | 3 h | attenuates Shikonin induced glioma cell death | 23840441 |
U87 | Cell Viability Assay | 1 mmol/L | 3 h | attenuates Shikonin induced glioma cell death | 23840441 |
C6 | Cytotoxicity Assay | 1 mmol/L | 3 h | blocks shikonin induced necrosis | 23840441 |
U87 | Cytotoxicity Assay | 1 mmol/L | 3 h | blocks shikonin induced necrosis | 23840441 |
C6 | Function Assay | 1 mmol/L | 1.5-3 h | suppresses the expression of RIP-1 caused by shikonin | 23840441 |
U87 | Function Assay | 1 mmol/L | 1.5-3 h | suppresses the expression of RIP-1 caused by shikonin | 23840441 |
TE671 | Cell Viability Assay | 40?μg/ml? | 24 h | rescues GX15-070-induced loss of cell viability | 23744296 |
RMS13 | Cell Viability Assay | 40?μg/ml? | 24 h | rescues GX15-070-induced loss of cell viability | 23744296 |
MEFs | Cytotoxicity Assay | 2/6/20 μM | 18 h | inhibits TNFα-induced cell death in RelA KO MEFs | 23727581 |
MEFs | Function Assay | 20?μM | 1/2/4 h | suppresses TNFα-induced RIPK1 phosphorylation | 23727581 |
ΔN-Karpas 299? | Cytotoxicity Assay | 20?μM | 16 h | inhibits CD30-induced cell death | 23545938 |
MM.1S? | Cytotoxicity Assay | 90 μM | 1 h | blocks BAY 11-7082 induced rapid cell swelling | 23527154 |
KMS-12-BM | Cytotoxicity Assay | 90 μM | 1 h | blocks BAY 11-7082 induced rapid cell swelling | 23527154 |
HT-22? | Cell Viability Assay | 10?μM | 12?h | protects against glutamate-induced cell death | 23307752 |
HT-22? | Function Assay | 25?μM | 0–30?min | inhibits ERK Activation induced by glutamate | 23307752 |
NIH3T3? | Function Assay | 10/50 μM | 1/3 h | ameliorates TNFα-driven complex formation | 23261677 |
SH-EP | Apoptosis Assay | 10?μM? | 72?h? | inhibits IAP inhibitor- and Lexatumumab-induced apoptosis | 22890322 |
HL60 | Apoptosis Assay | 60 μM | 12 h | enhances shikonin-induced apoptosis | 22837689 |
HL60/Adr | Apoptosis Assay | 60 μM | 12 h | enhances shikonin-induced apoptosis | 22837689 |
K562 | Apoptosis Assay | 60 μM | 12 h | enhances shikonin-induced apoptosis | 22837689 |
K562/Adr? | Apoptosis Assay | 60 μM | 12 h | enhances shikonin-induced apoptosis | 22837689 |
HL60 | Function Assay | 60 μM | 12 h | augments the caspase-3 activity | 22837689 |
HL60/Adr | Function Assay | 60 μM | 12 h | augments the caspase-3 activity | 22837689 |
K562 | Function Assay | 60 μM | 12 h | augments the caspase-3 activity | 22837689 |
K562/Adr? | Function Assay | 60 μM | 12 h | augments the caspase-3 activity | 22837689 |
HL60 | Function Assay | 60 μM | 12 h | increases the activity of caspases, caspase 8 and 9 | 22837689 |
HL60/Adr | Function Assay | 60 μM | 12 h | increases the activity of caspases, caspase 8 and 9 | 22837689 |
K562 | Function Assay | 60 μM | 12 h | increases the activity of caspases, caspase 8 and 9 | 22837689 |
K562/Adr? | Function Assay | 60 μM | 12 h | increases the activity of caspases, caspase 8 and 9 | 22837689 |
L929sA | Apoptosis Assay | 10 μM | 1 h | inhibits the apoptotic response to TNF | 22362767 |
L929sA | Apoptosis Assay | 10 μM | 1 h | rescues cells expressing RIPK1ΔID from TNF-induced apoptosis | 22362767 |
L929sA | Apoptosis Assay | 10 μM | 1 h | abrogates the interaction of caspase-8 with FADD | 22362767 |
TPC-1 | Cell Viability Assay | 100 μM | 24 h | increases cellular survival | 22136818 |
8505c | Cell Viability Assay | 100 μM | 24 h | increases cellular survival | 22136818 |
SW13 | Cell Viability Assay | 100 μM | 24 h | increases cellular survival | 22136818 |
Jurkat? | Cytotoxicity Assay | 50/ 100/200?μm | 1/3 h | reduces?Naegleria fowleri-induced cytotoxicity | 21535020 |
Jurkat? | Function Assay | 200?μm | 30 min | reduces?Naegleria fowleri-induced reactive oxygen species (ROS) generation | 21535020 |
HT-22 | Cytotoxicity Assay | 10 μM | 12 h | protects against cell death induced by 5?mmol/L glutamate? | 17760869 |
L929 | Function Assay | 2/5?μg/ml? | 24?h | reversed the autophagy induced by TNFα alone as well as TNFα?+?zVAD | 23941769 |
NRK-52E? | Cell Viability Assay | 20 μM | 24 h | inhibits increased Drp1 protein expression after TNF-α Stimulation and ATP Depletion | 24351845 |
NRK-52E? | Cell Viability Assay | 20 μM | 24 h | increases cell viability after TNF-α Stimulation and ATP Depletion | 24351845 |
NRK-52E? | Cell Viability Assay | 20 μM | 24 h | protects cells from cell death caused by ischemia injury | 24351845 |
AGS | Cell Viability Assay | 60?μm | 1?h | prevents shikonin-induced cell death | 24463199 |
L-540? | Cell Viability Assay | 60?μm | 1?h | reduces the Givinostat/Sorafenib-induced cell death | 24561519 |
L-540? | Function Assay | 60?μm | 1?h | prevents the mitochondrial membrane depolarization | 24561519 |
L-540? | Function Assay | 60?μm | 1?h | prevents the generation of ROS | 24561519 |
SK-Hep1 | Function Assay | 60?μM? | 18?h | blocks?β-lapachone-mediated PAR accumulation and AIF translocation to the cytosol? | 24832602 |
SK-Hep1 | Function Assay | 60?μM? | 18?h | inhibits β-Lapachone-induced leakage of HMGB-1? | 24832602 |
SK-Hep1 | Function Assay | 60?μM? | 18?h | blocks?β-lapachone-induced morphological change, cell death and PI uptake | 24832602 |
Huh7 | Cell Viability Assay | 50 μM | 24/48 h | prevents cell death of rAdHCV co-infected Huh7 cells | 24973240 |
L929 | Cell Viability Assay | 30?μM | 1?h | inhibits TNF-α-induced cleavage of Topo I | 25095742 |
L929 | Cell Viability Assay | 30?μM | 1?h | inhibits TNF-α-induced loss of cell viability | 25095742 |
L929-A | Function Assay | 50?μM? | 12 h | inhibits the TNFα-induced loss of mitochondrial membrane permeability | 25398540 |
L929 | Function Assay | 50?μM? | 12 h | inhibits TNFα-induced Bid cleavage | 25398540 |
L929-N? | Function Assay | 50?μM? | 12 h | blocks the cleavage of Caspase-3 and PARP | 25398540 |
L929-A? | Function Assay | 50?μM? | 12 h | blocks the cleavage of Caspase-3 and PARP | 25398540 |
L929-N? | Cell Viability Assay | 50?μM? | 24 h | blocks TNFα-induced cell death | 25398540 |
L929-A? | Cell Viability Assay | 50?μM? | 24 h | blocks TNFα-induced cell death | 25398540 |
KMS-12-PE? | Cell Viability Assay | 60 μM | 5 h | inhibits SHK-induced cell death | 25530098 |
SGC-7901 | Cell Viability Assay | 30?μM | 1?h | suppresses oxaliplatin-mediated cell death | 25767076 |
BxPC-3 | Function Assay | 20 μM | 24 h | decreases the early necrotic cells | 26000607 |
MiaPaCa-2 | Function Assay | 20 μM | 24 h | decreases the early necrotic cells | 26000607 |
NCI-H28 | Cell Viability Assay | 10?μM | 24?h | prevents DAPE-induced reduction of NCI-H28 cell viability? | 26004138 |
BMDM? | Function Assay | 10?μM | 30?min | protects cells from TAKI-induced LDH release | 26381601 |
MEFs? | Cell Viability Assay | 10?μM | 48 h | inhibits zVAD-promoted death of CNOT3-depleted MEFs | 26437789 |
A549 | Cell Viability Assay | 50?μM | 24?h | inhibits MMS-induced cell death | 26472723 |
Jurkat T | Necroptosis assay | 30 uM | 24 hrs | Inhibition of necroptosis in TNF-alpha-induced human Jurkat T cells assessed as cell viability at 30 uM after 24 hrs | 18467094 |
L929 | Necroptosis assay | 30 uM | 24 hrs | Inhibition of necroptosis in zVAD-induced mouse L929 cells assessed as cell viability at 30 uM after 24 hrs | 18467094 |
L929 | Necroptosis assay | 30 uM | 24 hrs | Inhibition of necroptosis in TNF-alpha-induced mouse L929 cells assessed as cell viability at 30 uM after 24 hrs | 18467094 |
Jurkat | Cytoprotective assay | 30 uM | 1 hr | Cytoprotective activity against FasL-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by FasL stimulation measured after 20 hrs by Alamar blue assay | 29541357 |
Jurkat | Cytoprotective assay | 30 uM | 1 hr | Cytoprotective activity against CHX-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by CHX stimulation by Alamar blue assay | 29541357 |
Jurkat | Cytoprotective assay | 30 uM | 1 hr | Cytoprotective activity against Z-VAD-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by Z-VAD stimulation by Alamar blue assay | 29541357 |
Jurkat | Cytoprotective assay | 30 uM | 1 hr | Cytoprotective activity against FasL-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by FasL stimulation measured after 20 hrs by phase contrast microscopy | 29541357 |
Jurkat | Cytoprotective assay | 30 uM | 1 hr | Cytoprotective activity against CHX-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by CHX stimulation by phase contrast microscopy | 29541357 |
Jurkat | Cytoprotective assay | 30 uM | 1 hr | Cytoprotective activity against Z-VAD-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by Z-VAD stimulation by phase contrast microscopy | 29541357 |
OHC | Function Assay | 300?μM | increases the number of apoptotic OHCs without altering the levels of CC8 after noise exposure | 24874734 | |
OHC | Function Assay | 300?μM | diminishes noise-induced AMPK activation | 24874734 | |
OHC | Function Assay | 300?μM | results in a reduction of noise-induced RIP1 and RIP3 immunofluorescence | 24874734 | |
OHC | Function Assay | 300?μM | decreases noise-induced swollen nuclei? | 24874734 | |
OHC | Function Assay | 300?μM | increases noise-induced condensed nuclei | 24874734 | |
Sf9 | Function assay | 30 mins | Inhibition of recombinant human GST-fused RIPK1 (1 to 497 residues) expressed in baculovirus infected insect Sf9 cells in presence of 32P-gamma-ATP after 30 mins by autoradiogram-based Western blot method, IC50 = 0.182 μM. | 28280261 | |
3T3 | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necrotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha and zVAD.fmk | 16408008 | |
3T3 | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necrotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of FasL and zVAD.fmk | 16408008 | |
MEF | Cell death assay | 16 hrs | Inhibition of death receptor signaling mediated necrotic cell death in SV40 transformed mouse MEF cells assessed as cell viability after 16 hrs by ATP based viability assay in presence of TNFalpha, CHX and zVAD.fmk | 16408008 | |
L929 | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necrotic cell death in mouse L929 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha | 16408008 | |
U937 | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human U937 cells assessed as cell viability after 48 hrs by ATP based viability assay in presence of TNFalpha and zVAD-fmk | 16408008 | |
3T3 | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha and zVAD-fmk | 16408008 | |
Jurkat | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD assessed as decreased levels of PE-conjugated LC3-II (autophagy marker) after 24 hrs by Western blot method in presence of TNFalpha | 16408008 | |
L929 | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in mouse L929 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of TNFalpha | 16408008 | |
3T3 | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of TNFalpha and zVAD-fmk | 16408008 | |
3T3 | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of FasL and zVAD-fmk | 16408008 | |
3T3 | Cell death assay | 24 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of rapamycin | 16408008 | |
Jurkat | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing FKBP12-based dimerization domain assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk | 16408008 | |
Jurkat | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk | 16408008 | |
Jurkat | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP K45M mutant assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk | 16408008 | |
Jurkat | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase domain assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk | 16408008 | |
Jurkat | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing FKBP12-based dimerization domain assessed as cell viability after 48 hrs by FACS in presence of AP1510 | 16408008 | |
Jurkat | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase assessed as cell viability after 48 hrs by FACS in presence of AP1510 | 16408008 | |
Jurkat | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP K45M mutant assessed as cell viability after 48 hrs by FACS in presence of AP1510 | 16408008 | |
Jurkat | Cell death assay | 48 hrs | Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase domain assessed as cell viability after 48 hrs by FACS in presence of AP1510 | 16408008 | |
Jurkat T | Necroptosis assay | Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat T cells, EC50 = 0.05 μM. | 18467094 | ||
Jurkat | Function assay | Inhibition of endogenous RIP1 autophosphorylation in human Jurkat cells, EC50 = 0.182 μM. | 18408713 | ||
Jurkat T | Necroptosis assay | Effective concentration required for inhibition of necroptosis in FADD deficient Jurkat T cells treated with TNF-alpha, EC50 = 0.49 μM. | 16153840 | ||
Jurkat | Necroptosis assay | Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells, EC50 = 0.49 μM. | 18408713 | ||
IEC18 | Cell death assay | Inhibition of death receptor signaling mediated necrotic cell death in rat IEC18 cells assessed as cell viability in presence of TNFalpha and zVAD.fmk | 16408008 | ||
HL60 | Cell death assay | Inhibition of death receptor signaling mediated necrotic cell death in human HL60 cells assessed as cell viability in presence of TNFalpha and zVAD.fmk | 16408008 | ||
Jurkat | Necrosis assay | Inhibition of necrosis in human Jurkat cells assessed as nuclear condensation by bright field microscopy in presence of FasL, CHX and zVAD-fmk | 16408008 | ||
Jurkat | Necrosis assay | Inhibition of necrosis in human Jurkat cells assessed as organelle swelling by bright field microscopy in presence of FasL, CHX and zVAD-fmk | 16408008 | ||
Jurkat | Necrosis assay | Inhibition of necrosis in human Jurkat cells assessed as early loss of plasma membrane integrity by bright field microscopy in presence of FasL, CHX and zVAD-fmk | 16408008 | ||
Jurkat | Necrosis assay | Inhibition of necrosis in human Jurkat cells assessed as appearance of translucent cytosol in presence of FasL, CHX and zVAD-fmk | 16408008 | ||
Jurkat | Necrosis assay | Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of nuclear condensation by bright field microscopy in presence of TNFalpha | 16408008 | ||
Jurkat | Necrosis assay | Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of organelle swelling by bright field microscopy in presence of TNFalpha | 16408008 | ||
Jurkat | Necrosis assay | Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of early loss of plasma membrane integrity by bright field microscopy in presence of TNFalpha | 16408008 | ||
Jurkat | Necrosis assay | Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of appearance of translucent cytosol in presence of TNFalpha | 16408008 | ||
Sf9 | Function assay | Inhibition of human RIP1 K45M mutant autophosphorylation expressed in Sf9 cells | 18408713 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Necrostatin-1 (Nec-1)是一種特異性RIP1 (RIPK1)抑制劑,抑制TNF-α誘導的細胞壞死,在293T細胞中EC50為490 nM。Necrostatin-1也可抑制 IDO、細胞自噬和凋亡。 | ||||
---|---|---|---|---|---|
特性 | Necrostatin-1是抑制細胞壞死的有力工具。 | ||||
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Necrostatin-1 (1-100 μM) 抑制過表達和內(nèi)源性的RIP1發(fā)生自磷酸化。RIP1是初級細胞靶點,負責Necrostatin-1的抗細胞壞死活性。[1] Necrostatin-1有效抑制多種類型細胞觸發(fā)的壞死性細胞死亡。Necrostatin-1作為細胞壞死的小分子抑制劑, 作用于jurkat細胞,抑制RIP激酶的誘導細胞壞死,抑制TNF-α誘導的細胞壞死,EC50為490 nM。[2] |
|||
---|---|---|---|---|
激酶實驗 | RIP1 激酶檢測 | |||
RIP1 的磷酸化需要其激酶活性。FLAG標記的野生型(WT)或RIP1(K45M) 突變體失活激酶的表達結(jié)構(gòu)轉(zhuǎn)染到293T細胞中,在有[γ-32P]ATP存在時,RIP1激酶實驗在30°C下進行30分鐘。樣品進行SDS-PAGE,通過放射自顯影可觀察到RIP1帶。對放射性帶的相對強度進行量化,并顯示比率。在激酶反應的同時,珠樣本使用anti-RIP1抗體進行Western Blot分析,確保與激酶反應中等量的蛋白。 | ||||
細胞實驗 | 細胞系 | Jurkat, BALB/c 3T3, SV40-轉(zhuǎn)化的MEF, L929 | ||
濃度 | 0.01-100 μM | |||
孵育時間 | -- | |||
方法 | 細胞接種在96孔板中(白色板進行發(fā)光檢測;黑色板進行熒光檢測;空白板進行MTT實驗)貼壁細胞按每孔5000-10000個細胞的密度接種,懸浮細胞按每孔20,000-50,000個細胞的密度接種,孔中含100 μl合適的無酚紅培養(yǎng)基。溫育后,使用如下方法之一測定細胞存活率。ATP 實驗中,使用購買的發(fā)光試劑盒,并使用Wallac Victor II酶標儀分析發(fā)光值。Sytox實驗中,細胞與 1 μM Sytox Green試劑在37°C下溫育30分鐘,然后進行熒光讀數(shù)。隨后,增加5 μl 20% Triton X-100溶液到每孔中,產(chǎn)生最大溶解,細胞37°C下溫育1小時,然后進行二次讀數(shù)。Triton處理前和后,計算值的比率。MTT實驗,使用CellTiter 96 AQueous 非放射性細胞增殖檢測試劑盒。PI排除實驗中, 加入2 μg/ml PI 到培養(yǎng)基中,立即使用FACSCalibur分析樣品。PI-膜聯(lián)蛋白V 實驗中,使用ApoAlert Annexin V-EGFP 凋亡試劑盒。進行DioC6染色, 細胞與40 nM DiOC6 在37°C下溫育30分鐘, 洗滌一次,使用FACSCalibur分析。ROS分析中, 細胞與5 μM Dihydroethidium在37°C下溫育30分鐘, 洗滌一次,使用FACSCalibur分析。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Immunofluorescence | RIP1 / RIP3 |
![]() |
30462730 |
分子量 | 259.33 | 分子式 | C13H13N3OS |
CAS號 | 4311-88-0 | SDF | Download Necrostatin-1 SDF |
Smiles | CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32 | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 57 mg/mL ( (219.79 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解配方 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項